BiosYnth Reasearch Laboratories
Biotechnology Research • 
Rapolano Terme, Tuscany, Italy • 1-10 Employees
Company overview
| Headquarters | Rapolano Terme, Tuscany, Italy |
| Phone number | +390577704685 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Farmaceutica, Ricerca E Sviluppo, Biotecnologie, Vaccini |
| Founded | 1988 |
| Employees | 1-10 |
| Socials |
Key Contact at BiosYnth Reasearch Laboratories
Massimo Porro
Founder, President & Scientific Director
BiosYnth Reasearch Laboratories Email Formats
BiosYnth Reasearch Laboratories uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@biosynthsrl.it), used 66.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@biosynthsrl.it | 66.7% |
{first name}.{last name} | john.doe@biosynthsrl.it | 33.3% |
About BiosYnth Reasearch Laboratories
BiosYnth Research Laboratories is a biotech Company focused on the discovery of novel synthetic and semi-synthetic molecules for application as human vaccines in the prevention of serious bacterial diseases like Invasive Pneumococcal Diseases (IPD) and Bacterial Meningitis due to pneumococcal and meningococcal infections. The Company was founded in 1988 by Dr. Massimo Porro on the basis of his pioneering activity in the design and industrial development of CRM 197-based glycoconjugate vaccines for the prevention of bacterial meningitis in infants and young children due to Gram-negative and Gram-positive encapsulated bacteria. Some of these glycoconjugate vaccines, which involved the non-toxic mutant diphtheria protein CRM197 covalently linked to capsular polysaccharides and oligosaccharides derived from the capsule of Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae, are now manufactured and marketed in USA and Europe by two major vaccine producers. The Company’s commercial strategy is that of Licensing third Parties with its proprietary know-how, protected by a technological body of several International Patents, including USA and Europe, relative to the molecular entities designed and developed as vaccines for diseases having broad impact in the public health. The Licensing strategy includes the Technology Transfer of the production processes and the technical assistance for implementing the large-scale production processes. Several cooperations have been implemented in the past more than two decades with the most renowned Companies of the western world producing vaccines for human use. Since the year 2008, a new broad cooperation has been opened in the territory of the P.R. of China for producing polyvalent meningococcal and pneumococcal glycoconjugate vaccines with a modern technology but at an affordable price for the paediatric population of that country.
BiosYnth Reasearch Laboratories revenue & valuation
| Annual revenue | $598,885 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $2,000,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
BiosYnth Reasearch Laboratories has 4 employees across 4 departments.
Departments
Number of employees
Funding Data
BiosYnth Reasearch Laboratories has never raised funding before.
BiosYnth Reasearch Laboratories Tech Stack
Discover the technologies and tools that power BiosYnth Reasearch Laboratories's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Tag managers
Reverse proxies
Programming languages
Security
Miscellaneous
Video players
JavaScript libraries
UI frameworks
Video players
Analytics
JavaScript libraries
United States
United Kingdom
Frequently asked questions
4.8
40,000 users
